Although PPARγ agonists inhibit colorectal carcinogenesis inxenograft models and in the azoxymethane (AOM)-induced colon cancer model [43, 44], these drugs are reported to have bothtumor-promoting and tumor-inhibiting effects in a mouse model for familialadenomatous polyposis, the ApcMin/+ mouse. Here, PPARG is linked to colonic neoplasm.